£1.45 million grant from Innovate UK Biomedical Catalyst Funds enable IGEM Therapeutics to progress second product candidate towards the clinic London, 9 May 2018 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel...
May 9, 2018 - Press Releases